Research on complement: old issues revisited and a novel sphere of influence

被引:5
作者
Clemenza, L
Dieli, F
Cicardi, M
Salerno, A
机构
[1] Univ Milan, Dept Internal Med, I-20122 Milan, Italy
[2] Maggiore Hosp, IRCCS, I-20122 Milan, Italy
[3] Univ Palermo, Dept Biopathol & Biomed Methodol, I-90134 Palermo, Italy
关键词
D O I
10.1016/S1471-4906(03)00118-2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Immunology in recent years has taken a somewhat surprising turn, expressed by a renewed interest in innate immunity. Especially intriguing is the regulatory role exerted by the innate components on the adaptive response, with Toll receptors and complement components being the most investigated. This function has been firmly established for complement protein CR2 (CD21) as part of the BCR co-receptor CD19/CD21/CD81. New findings are now providing a broader picture of complement and its tuning of the immune response; for example, complement proteins have been implicated in the control of T-cell-mediated responses. We will review some of these data here and summarize new discoveries in areas of research on more traditional topics within the complement literature, such as complement and renal diseases, and the therapeutic use of Cl-Inhibitor. We cover papers selected from studies presented at the XIX International Complement Workshop, held in Palermo in September 2002, and published within the past six months.
引用
收藏
页码:293 / 296
页数:4
相关论文
共 25 条
[1]   Contribution of anaphylatoxin C5a to late airway responses after repeated exposure of antigen to allergic rats [J].
Abe, M ;
Shibata, K ;
Akatsu, H ;
Shimizu, N ;
Sakata, N ;
Katsuragi, T ;
Okada, H .
JOURNAL OF IMMUNOLOGY, 2001, 167 (08) :4651-4660
[2]   Factor H and the pathogenesis of renal diseases [J].
Ault, BH .
PEDIATRIC NEPHROLOGY, 2000, 14 (10-11) :1045-1053
[3]  
Caliezi C, 2000, PHARMACOL REV, V52, P91
[4]   HETEROGENEITY OF NEPHRITIC FACTOR AND ITS IDENTIFICATION AS AN IMMUNOGLOBULIN - (COMPLEMENT ALTERNATIVE PATHWAY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS PARTIAL LIPODYSTROPHY) [J].
DAVIS, AE ;
ZIEGLER, JB ;
GELFAND, EW ;
ROSEN, FS ;
ALPER, CA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1977, 74 (09) :3980-3983
[5]   Neuroprotection by complement (C1) inhibitor in mouse transient brain ischemia [J].
De Simoni, MG ;
Storini, C ;
Barba, M ;
Catapano, L ;
Arabia, AM ;
Rossi, E ;
Bergamaschini, L .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2003, 23 (02) :232-239
[6]   Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction [J].
de Zwaan, C ;
Kleine, AH ;
Diris, JHC ;
Glatz, JFC ;
Wellens, HJJ ;
Strengers, PFW ;
Tissing, M ;
Hack, CE ;
van Dieijen-Visser, MP ;
Hermens, WT .
EUROPEAN HEART JOURNAL, 2002, 23 (21) :1670-1677
[7]   Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy [J].
Drouin, SM ;
Corry, DB ;
Hollman, TJ ;
Kildsgaard, J ;
Wetsel, RA .
JOURNAL OF IMMUNOLOGY, 2002, 169 (10) :5926-5933
[8]   Increased vascular permeability in C1 men inhibitor-deficient mice mediated by the bradykinin type 2 receptor [J].
Han, ED ;
MacFarlane, RC ;
Mulligan, AN ;
Scafidi, J ;
Davis, AE .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (08) :1057-1063
[9]   Complementing asthma [J].
Henson, P .
NATURE IMMUNOLOGY, 2000, 1 (03) :190-192
[10]   Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein [J].
Huang, J ;
Kim, LJ ;
Mealey, R ;
Marsh, HC ;
Zhang, Y ;
Tenner, AJ ;
Connolly, ES ;
Pinsky, DJ .
SCIENCE, 1999, 285 (5427) :595-599